See more : Bang Overseas Limited (BANG.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (CLSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kyokuto Securities Co., Ltd. (8706.T) Income Statement Analysis – Financial Results
- Berry Global Group, Inc. (0HN1.L) Income Statement Analysis – Financial Results
- Main Street Capital Corporation (MAIN) Income Statement Analysis – Financial Results
- Glass House Brands Inc. (GHBWF) Income Statement Analysis – Financial Results
- West Coast Paper Mills Limited (WSTCSTPAPR.NS) Income Statement Analysis – Financial Results
Imunon, Inc. (CLSN)
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 11.25M | 12.32M | 2.51M | 0.00 | 0.00 | 0.00 | 3.42K | 100.00K | 174.18K | 121.26K | 74.01K |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67M | 8.11M | 2.10M | 0.00 | 0.00 | 0.00 | -39.23K | 0.00 | 136.50K | 46.73K | 64.41K |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 4.58M | 4.21M | 405.34K | 0.00 | 0.00 | 0.00 | 42.65K | 100.00K | 37.68K | 74.52K | 9.60K |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 40.72% | 34.15% | 16.17% | 0.00% | 0.00% | 0.00% | 1,247.13% | 100.00% | 21.63% | 61.46% | 12.97% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M | 19.86M | 14.71M | 13.68M | 12.01M | 8.23M | 9.35M | 10.08M | 11.53M | 8.18M | 5.00M | 4.08M | 2.24M | 1.00M | 1.53M | 185.97K | 94.01K |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 0.00 | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 0.00 | 0.00 | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 390.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 5.15M | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 3.47M | 5.13M | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Other Expenses | 0.00 | 5.40M | 1.62M | -1.30M | 3.19M | 3.63M | 651.97K | 733.00K | -259.45K | 265.89K | -2.53K | -1.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 14.08M | 13.49M | 15.00M | 13.30M | 9.84M | 7.29M | 4.94M | 2.40M | 4.05M | 2.47M | 1.43M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 20.75M | 21.60M | 17.11M | 13.30M | 9.84M | 7.29M | 4.90M | 2.40M | 4.19M | 2.52M | 1.50M |
| Interest Income | 960.55K | 502.58K | 18.15K | 66.55K | 442.99K | 331.78K | 26.04K | 31.26K | 186.32K | 1.02M | 748.95K | 0.00 | 174.06K | 32.29K | 46.16K | 221.71K | 0.00 | 636.56K | 299.25K | 0.00 | 30.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.57M | 557.00K | 1.29M | 1.39M | 712.03K | 91.76K | 693.00K | 1.36M | 1.33M | 915.24K | 307.00K | 501.86K | 31.52K | 94.92K | 141.61K | 49.42M | 1.10M | 179.59K | 0.00 | -13.27M | -9.75M | -6.92M | 0.00 | 0.00 | 199.35K | 0.00 | 85.51K |
| Depreciation & Amortization | 720.01K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 424.97K | 369.33K | 339.23K | 281.49K | 176.86K | 172.98K | 109.65K | 69.47K | -39.11K | -341.29K | -321.39K | -275.68K | 100.53K | 82.44K | 68.85K | 39.48K | -100.00K | 24.29K | 24.17K | 18.55K |
| EBITDA | -19.88M | -31.71M | -20.88M | -21.30M | -16.55M | -21.23M | -19.76M | -20.30M | -20.67M | -23.79M | -6.99M | -25.92M | -22.54M | -18.61M | -15.80M | -11.58M | -13.13M | -9.84M | -9.50M | -14.78M | -13.20M | -9.79M | -7.26M | -4.86M | -2.40M | -3.99M | -2.37M | -1.40M |
| EBITDA Ratio | 0.00% | -3,905.20% | -3,877.00% | -3,795.72% | -3,242.17% | -3,349.10% | -3,447.48% | -3,983.40% | -4,098.99% | -4,335.91% | -2,865.17% | 0.00% | -1,133.39% | 0.00% | 0.00% | -463.01% | 0.00% | -94.55% | -77.14% | -589.83% | 0.00% | 0.00% | 0.00% | -142,016.75% | -2,300.00% | -2,296.79% | -1,960.88% | -1,936.39% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -24.72M | -15.41M | -22.14M | -23.02M | -19.64M | -17.01M | -11.55M | -13.59M | -8.49M | -9.28M | -14.60M | -13.30M | -9.84M | -7.29M | -4.90M | -2.30M | -4.01M | -2.39M | -1.42M |
| Operating Income Ratio | 0.00% | -4,984.40% | -4,201.40% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,130.00% | -4,169.36% | -4,943.04% | -3,082.30% | 0.00% | -1,150.94% | 0.00% | 0.00% | -461.98% | 0.00% | -75.43% | -75.32% | -582.51% | 0.00% | 0.00% | 0.00% | -143,171.08% | -2,300.00% | -2,303.92% | -1,974.89% | -1,922.52% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -779.08K | 7.16M | -4.43M | -203.91K | 818.99K | 1.01M | -236.80K | -483.23K | 902.40K | -96.89K | 613.90K | 30.38K | 86.61K | 363.65K | 349.24K | -100.00K | -187.48K | -657.19K | -510.69K |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -16.00M | -11.79M | -14.07M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Income Before Tax Ratio | 0.00% | -7,493.00% | -4,430.60% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 1.93M | 1.40M | 1.61M | 779.08K | 1.00 | 4.43M | 203.91K | -818.99K | -806.00K | 236.80K | -49.42M | -1.91M | 8.69M | -613.90K | 13.27M | 9.75M | 6.92M | 4.55M | 2.40M | 187.48K | 657.19K | 510.69K |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -15.19M | -11.79M | 35.35M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Net Income Ratio | 0.00% | -7,179.60% | -4,153.80% | -4,296.71% | -3,370.31% | -2,376.67% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| EPS | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.43 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 3.11K | -668.10 | -765.29 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -105.01 | -1.52K | -1.09K |
| EPS Diluted | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.42 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 2.90K | -668.10 | -760.54 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -193.97 | -1.52K | -1.09K |
| Weighted Avg Shares Out | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 11.36K | 11.35K | 11.35K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 40.00K | 2.00K | 1.78K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 12.18K | 11.35K | 11.42K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 21.66K | 2.00K | 1.78K |
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment...
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne Le Goff - President & CEO Jeffrey Church - CFO Nicholas...
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss...
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Michael H. Tardugno appointed Executive Chairman of the Board
Source: https://incomestatements.info
Category: Stock Reports